NICE National Institute for Health and Care Excellence



Empagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction

Information for the public Published: 1 November 2023

www.nice.org.uk

Empagliflozin (Jardiance) is available on the NHS. It is a possible treatment for symptomatic chronic heart failure with preserved or mildly reduced ejection fraction in adults.

Preserved or mildly reduced ejection fraction is when more than 40% of the blood in the left ventricle of the heart is pumped to the body in each heartbeat.

Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. See <u>our webpage on making decisions about your care</u>.

Empagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction

Questions to think about

- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?

Information and support

The <u>NHS webpage on heart failure</u> may be a good place to find out more.

The Pumping Marvellous Foundation (01772 796 542) can give you advice and support.

You can also get support from your local <u>Healthwatch</u>.

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-5517-6